Franklin Resources Inc. trimmed its position in Organon & Co. (NYSE:OGN - Free Report) by 8.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 313,369 shares of the company's stock after selling 30,769 shares during the period. Franklin Resources Inc. owned approximately 0.12% of Organon & Co. worth $4,675,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of OGN. Horizon Bancorp Inc. IN raised its stake in shares of Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company's stock worth $25,000 after purchasing an additional 1,585 shares in the last quarter. Millstone Evans Group LLC bought a new stake in Organon & Co. during the fourth quarter worth $29,000. Larson Financial Group LLC lifted its stake in Organon & Co. by 345.4% in the fourth quarter. Larson Financial Group LLC now owns 2,236 shares of the company's stock valued at $33,000 after acquiring an additional 1,734 shares during the last quarter. Riverview Trust Co grew its position in shares of Organon & Co. by 117.7% in the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company's stock valued at $36,000 after acquiring an additional 1,292 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock worth $41,000 after purchasing an additional 672 shares during the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.
Organon & Co. Stock Performance
Shares of NYSE OGN traded down $0.20 during trading hours on Tuesday, reaching $11.10. 1,828,011 shares of the stock were exchanged, compared to its average volume of 2,650,330. The firm has a market capitalization of $2.86 billion, a price-to-earnings ratio of 3.33, a P/E/G ratio of 0.90 and a beta of 0.73. The stock's fifty day simple moving average is $14.56 and its 200 day simple moving average is $15.59. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a 52 week low of $10.94 and a 52 week high of $23.10.
Organon & Co. (NYSE:OGN - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Sell-side analysts predict that Organon & Co. will post 3.68 EPS for the current year.
Organon & Co. Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.09%. Organon & Co.'s payout ratio is presently 33.63%.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. TD Cowen upgraded Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Barclays reduced their target price on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Finally, Morgan Stanley dropped their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $20.60.
Check Out Our Latest Analysis on OGN
Organon & Co. Company Profile
(
Free Report)
Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
See Also
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
